An MXene–graphene field-effect transistor (FET) sensor for both influenza virus and 2019-nCoV sensing was developed and characterized. The developed sensor combines the high chemical sensitivity of MXene and the continuity of large-area high-quality graphene to form an ultra-sensitive virus-sensing transduction material (VSTM). Through polymer linking, we are able to utilize antibody–antigen binding to achieve electrochemical signal transduction when viruses are deposited onto the VSTM surface. The MXene–graphene VSTM was integrated into a microfluidic channel that can directly receive viruses in solution. The developed sensor was tested with various concentrations of antigens from two viruses: inactivated influenza A (H1N1) HA virus ranging from 125 to 250,000 copies/mL and a recombinant 2019-nCoV spike protein ranging from 1 fg/mL to 10 pg/mL. The average response time was about ∼50 ms, which is significantly faster than the existing real-time reverse transcription-polymerase chain reaction method (>3 h). The low limit of detection (125 copies/mL for the influenza virus and 1 fg/mL for the recombinant 2019-nCoV spike protein) has demonstrated the sensitivity of the MXene–graphene VSTM on the FET platform to virus sensing. Especially, the high signal-to-viral load ratio (∼10% change in source-drain current and gate voltage) also demonstrates the ultra-sensitivity of the developed MXene–graphene FET sensor. In addition, the specificity of the sensor was also demonstrated by depositing the inactivated influenza A (H1N1) HA virus and the recombinant 2019-nCoV spike protein onto microfluidic channels with opposite antibodies, producing signal differences that are about 10 times lower. Thus, we have successfully fabricated a relatively low-cost, ultrasensitive, fast-responding, and specific inactivated influenza A (H1N1) and 2019-nCoV sensor with the MXene–graphene VSTM.
Development and comparison of the latent fingerprints (LFPs) are two major studies in detection and identification of LFPs, respectively. However, integrated research studies on both fluorescent materials for LFP development and digital-processing programs for LFP comparison are scarcely seen in the literature. In this work, highly efficient red-emissive carbon dots (R-CDs) are synthesized in one pot and mixed with starch to form R-CDs/starch phosphors. Such phosphors are comparable with various substrates and suitable for the typical powder dusting method to develop LFPs. The fluorescence images of the developed LFPs are handled with an artificial intelligence program. For the optimal sample, this program presents an excellent matching score of 93%, indicating that the developed sample has very high similarity with the standard control. Our results are significantly better than the benchmark obtained by the traditional method, and thus, both the R-CDs/starch phosphors and the digital processing program fit well for the practical applications.
Long noncoding RNA (lncRNA) AGAP2 antisense RNA 1 (AGAP2-AS1) has been suggested to function as an oncogenic lncRNA in lung cancer, breast cancer, and anaplastic glioma. However, the expression pattern and molecular mechanism of AGAP2-AS1 in glioblastoma multiforme (GBM) remains unknown. The purpose of this study is to present more evidence about the clinical and biological function of AGAP2-AS1 in GBM. In our results, we found AGAP2-AS1 expression was increased in GBM compared with adjacent normal brain tissues or low-grade glioma tissues, and there was no significantly different between low-grade glioma tissues and normal tissues. Kaplan-Meier survival analysis indicated patients with GBM having high-expression of AGAP2-AS1 had shorter overall survival time than those with low expression of AGAP2-AS1. The loss-of-function studies showed that downregulation of AGAP2-AS1 depressed cell proliferation, migration, and invasion, and promoted cell apoptosis in GBM. In summary, AGAP2-AS1 is a prognostic biomarker for patients with GBM, and functions as an oncogenic lncRNA to modulate GBM cell proliferation, apoptosis, migration, and invasion, which suggests that AGAP2-AS1 is potential therapeutic target for GBM. K E Y W O R D S AGAP2-AS1, GBM, glioblastoma multiforme, glioma, lncRNA J Cell Biochem. 2019;120:9056-9062. wileyonlinelibrary.com/journal/jcb 9056 |
As a class of electrode materials for electric double-layer capacitors (EDLCs), carbon dots (CDs) are able to enlarge specific surface areas, fabricate hierarchical pores, and graft pseudocapacitive groups, leading to additional capacities and superior energy densities. In this work, the commercial polyacrylamide gel (PAMG) is used as a good host for CDs, which has continuously interconnected pores, a cross-linked network, and good swelling capacity so as to form continuous conductive carbon skeleton. After a one-step calcination–activation treatment, CDs are fused onto the final carbon architecture to form a series of porous carbon materials with specific functional groups. Different kinds of CDs, including the oxygen-doped, the nitrogen-doped, and the oxygen, nitrogen co-doped ones, are employed to prepare such carbon materials and tested, respectively. All of these materials have high specific surface areas, well-balanced pore size distributions, high conductivity, abundant superficial functional groups, and good wettability. When they are assembled as electrodes in EDLC, they exhibit remarkable performances, such as specific capacitance of 401–483 F g–1, rate stability over 75% (1–30 A g–1), energy density of 17–23 Wh kg–1, and cycling life of nearly 100%. These results prove that our method, calcination–activation on the CDs–porous (hydro)gel composites, is a universal route of preparing good carbon electrode materials for electrochemical energy storage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.